The aim of this study is to explore the potential implication of RPSA as prognostic biomarker of PDAC.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients treated at the Reims University Hospital for a resectable or potentially resectable pancreatic tumor, with or without neoadjuvant chemotherapy
Adults (aged more than 18 years old)
Patients who have signed the informed consent form
You may not be if
Patients with a prior history of cancer (excluding basal cell carcinoma or in situ cervical cancer that received conventional cancer treatment).
Minors
Patients for whom PDAC is not the retained diagnosis
Clareo Health | RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer
